About Biogenity

We take great pride in guiding you from sample to biology, tying it all together with our easy-to-follow reports and powerful tools for interpretation. Our mission is to assist omics discovery by empowering researchers, like you, with our expertise to get the most out of the omics analysis. Our vision is to advance omics research and bring better healthcare to future generations.

Latest news from Biogenity

Biogenity Partners with Centre for Diagnostics at DTU to Expand with Olink Proteomics Workflows

February 28, 2024 | By Louis Loeb

Are you searching for diagnostic or prognostic markers when performing large cohort studies, assessing the effect of treatments, or conducting basic research? We at Biogenity are excited to announce our new partnership with the Centre for Diagnostics at DTU. This alliance marks a significant milestone for the life science community, offering a streamlined, end-to-end workflow from sample to biological insight, utilizing the comprehensive capabilities of Olink proteomics and Biogenity’s data analysis pipeline.


Read the article More news

Meet the team

Kenneth K.
Kenneth Kastaniegaard, Ph.D.

Protein and applied AI expert

CEO & Co-founder
kkas@biogenity.com
Louis L.
Louis Loeb, M.Sc.

Marketing and UX domain expert

CCO & Co-founder
ll@biogenity.com
Alessandro R.
Alessandro Ranieri, M.Sc.

AI and back-end expert

Biomedical Engineer
ara@biogenity.com
Rune
Rune Larsen, Ph.D.

Scientist and omics expert

Biomedical Engineer
rhl@biogenity.com
Anezka
Anežka B. Forero, Ph.D. Fellow

Scientist and omics consultant

Biomedical Engineer
abf@biogenity.com
Christina
Christina V. Holler

Scientist and omics consultant

Biomedical Engineer
cvh@biogenity.com

Meet the Board of Advisors

Kim B.
Kim Budolph Johansen

Managing Director, Executive Coach & Leadership Advisor at Budolph ApS
Jesper K.
Jesper Kihl

Senior Advisor.
Former Vice President in Regulatory Affairs at LEO Pharma & Novo Nordisk
Peter Birk
Peter Birk

Partner at Accelerace Management A/S

Other R&D developments

Mapping exposure-induced immune effects

Horizon 2020 EXIMIOUS aims to deliver a new way of assessing the human exposome, i.e. the exposures to environmental factors that one experiences throughout life, and shed light on its association to immune-mediated diseases.

Biogenity contributes by building a neural network to identify potential causality among exposures and immune-related diseases using the DOC#X database.

Horizon 2020

EXIMIOUS

Corporate social responsibility

Plant a tree with Biogenity

Biogenity donates a dozen trees for every project delivered to support local communities, reforestation in the Amazon rainforest, and reducing CO2 emissions.

Partnering with One Tree Planted, we want to work towards a brighter future with better treatment for diseases and a healthy planet to enjoy life. For us, our children, grandchildren, and the generations to come.


Plant a tree